153 related articles for article (PubMed ID: 20298531)
1. Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors.
Singleton PA; Mambetsariev N; Lennon FE; Mathew B; Siegler JH; Moreno-Vinasco L; Salgia R; Moss J; Garcia JG
J Angiogenes Res; 2010 Feb; 2(1):5. PubMed ID: 20298531
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis.
Singleton PA; Garcia JG; Moss J
Mol Cancer Ther; 2008 Jun; 7(6):1669-79. PubMed ID: 18566238
[TBL] [Abstract][Full Text] [Related]
3. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation.
Singleton PA; Lingen MW; Fekete MJ; Garcia JG; Moss J
Microvasc Res; 2006; 72(1-2):3-11. PubMed ID: 16820176
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation.
Singleton PA; Moreno-Vinasco L; Sammani S; Wanderling SL; Moss J; Garcia JG
Am J Respir Cell Mol Biol; 2007 Aug; 37(2):222-31. PubMed ID: 17395891
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
Del Bufalo D; Ciuffreda L; Trisciuoglio D; Desideri M; Cognetti F; Zupi G; Milella M
Cancer Res; 2006 Jun; 66(11):5549-54. PubMed ID: 16740688
[TBL] [Abstract][Full Text] [Related]
6. Morphine promotes the malignant biological behavior of non-small cell lung cancer cells through the MOR/Src/mTOR pathway.
Liu X; Yang J; Yang C; Huang X; Han M; Kang F; Li J
Cancer Cell Int; 2021 Nov; 21(1):622. PubMed ID: 34823532
[TBL] [Abstract][Full Text] [Related]
7. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation.
Lin MT; Yen ML; Lin CY; Kuo ML
Mol Pharmacol; 2003 Nov; 64(5):1029-36. PubMed ID: 14573751
[TBL] [Abstract][Full Text] [Related]
9. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
10. 15(S)-hydroxyeicosatetraenoic acid induces angiogenesis via activation of PI3K-Akt-mTOR-S6K1 signaling.
Zhang B; Cao H; Rao GN
Cancer Res; 2005 Aug; 65(16):7283-91. PubMed ID: 16103079
[TBL] [Abstract][Full Text] [Related]
11. Effects of mTOR inhibitors and cytoskeletal-directed agents alone and in combination against normal and neoplastic hematopoietic cells in vitro.
Trendowski M; Christen TD; Andonova AA; Narampanawe B; Thibaud A; Kusang T; Fondy TP
Invest New Drugs; 2015 Dec; 33(6):1162-74. PubMed ID: 26490657
[TBL] [Abstract][Full Text] [Related]
12. The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors.
Dormond-Meuwly A; Roulin D; Dufour M; Benoit M; Demartines N; Dormond O
Biochem Biophys Res Commun; 2011 Apr; 407(4):714-9. PubMed ID: 21439267
[TBL] [Abstract][Full Text] [Related]
13. The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts.
Bozec A; Etienne-Grimaldi MC; Fischel JL; Sudaka A; Toussan N; Formento P; Milano G
Oral Oncol; 2011 May; 47(5):340-4. PubMed ID: 21421338
[TBL] [Abstract][Full Text] [Related]
14. Pravastatin induces rat aortic endothelial cell proliferation and migration via activation of PI3K/Akt/mTOR/p70 S6 kinase signaling.
Nakao T; Shiota M; Tatemoto Y; Izumi Y; Iwao H
J Pharmacol Sci; 2007 Dec; 105(4):334-41. PubMed ID: 18057776
[TBL] [Abstract][Full Text] [Related]
15. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer.
Janku F; Johnson LK; Karp DD; Atkins JT; Singleton PA; Moss J
Ann Oncol; 2016 Nov; 27(11):2032-2038. PubMed ID: 27573565
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma.
Lamanuzzi A; Saltarella I; Desantis V; Frassanito MA; Leone P; Racanelli V; Nico B; Ribatti D; Ditonno P; Prete M; Solimando AG; Dammacco F; Vacca A; Ria R
Oncotarget; 2018 Apr; 9(29):20563-20577. PubMed ID: 29755672
[TBL] [Abstract][Full Text] [Related]
17. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells.
Frost P; Shi Y; Hoang B; Lichtenstein A
Oncogene; 2007 Apr; 26(16):2255-62. PubMed ID: 17016437
[TBL] [Abstract][Full Text] [Related]
18. 5,3'-Dihydroxy-6,7,4'-trimethoxyflavanone exerts its anticancer and antiangiogenesis effects through regulation of the Akt/mTOR signaling pathway in human lung cancer cells.
Kim KM; Heo DR; Lee J; Park JS; Baek MG; Yi JM; Kim H; Bang OS
Chem Biol Interact; 2015 Jan; 225():32-9. PubMed ID: 25446852
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis.
Lennon FE; Mirzapoiazova T; Mambetsariev B; Salgia R; Moss J; Singleton PA
Anesthesiology; 2012 Apr; 116(4):857-67. PubMed ID: 22343475
[TBL] [Abstract][Full Text] [Related]
20. Silent Information Regulator 1 Negatively Regulates Atherosclerotic Angiogenesis via Mammalian Target of Rapamycin Complex 1 Signaling Pathway.
Chen R; Huang Z; Wang J; Chen X; Fu Y; Wang W
Am J Med Sci; 2018 Aug; 356(2):168-176. PubMed ID: 30219159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
